Genentech

What Genentech does

Genentech, Inc. is a US-based biotechnology research and biopharmaceutical company founded in 1976 in South San Francisco, California. It operates as a wholly-owned subsidiary of Roche Holding AG following Roche's 2009 acquisition for approximately $46.8 billion, serving as the primary US-based research, development, and commercialization vehicle for the Roche Group. The company develops, manufactures, and commercializes a broad portfolio of biologic and small-molecule medicines across five therapeutic areas: oncology (Tecentriq, Vabysmo, Hemlibra, Herceptin, Avastin, Polivy, Lunsumio, Columvi, Venclexta, Itovebi, Kadcyla, Perjeta, Phesgo, Rozlytrek, Alecensa, Zelboraf), immunology (Actemra, Rituxan, Gazyva, Xolair), neuroscience (Ocrevus, Enspryng, Evrysdi), ophthalmology (Vabysmo, Susvimo, Lucentis, Luxturna), and emerging areas including metabolic disease and obesity (enicepatide, petrelintide in Phase III). It maintains additional franchises in hematology (PiaSky) and infectious disease (Xofluza, Tamiflu).

Genentech's underlying technology combines established biologics manufacturing with AI/ML-augmented drug discovery. The Prescient Design platform provides machine learning-based protein design; a partnership with Recursion Pharmaceuticals extends AI-driven discovery into the clinic; and Roche's Galileo platform supports enterprise agentic AI for scientific discovery. Novel drug delivery technology includes the FDA-approved Port Delivery System (Susvimo), a refillable reservoir for continuous ranibizumab delivery in retinal disease, plus a growing set of subcutaneous reformulations (Phesgo, Ocrevus Zunovo, Tecentriq Hybreza, Rituxan Hycela, Lunsumio Velo) that improve convenience. Manufacturing scale is being expanded via a $700 million Holly Springs, North Carolina facility.

The business model centers on biopharmaceutical product sales through enterprise field sales, medical science liaisons, and specialty pharmacy distribution, complemented by Genentech Access Solutions for coverage support and the Genentech Patient Foundation, which provides free medicines to qualifying uninsured or underinsured patients. Revenue also includes co-commercialization economics, notably the joint U.S. commercialization of Venclexta with AbbVie. The company serves hospitals, oncology practices, neurology clinics, ophthalmology specialists, specialty pharmacies, and patients with serious and life-threatening diseases, with a 10,000+ employee base concentrated in South San Francisco and expanding US manufacturing operations.

Name

Genentech

Legal name

Genentech, Inc.

Website

https://gene.com

Company type

Private

Founded year

1976

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Genentech is a US-based biotechnology subsidiary of Roche Holding AG that develops and commercializes biologic and small-molecule medicines across oncology, immunology, neuroscience, ophthalmology, and metabolic disease, serving patients, hospitals, and specialty pharmacies worldwide.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Gene Therapy Regulatory, Pharmacovigilance & Clinical Operations Services (HLAAACAM)

Keywords

• Biopharmaceutical medicines
• Oncology therapeutics
• Immunology treatments
• Ophthalmology drugs
• Gene therapy

Headquarters

HQ city

South San Francisco

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Genentech generates revenue through sales of its portfolio of approved biopharmaceutical medicines across oncology, immunology, neuroscience, ophthalmology, and metabolic diseases. Products include Vabysmo, Tecentriq, Hemlibra, Ocrevus, Lucentis, Avastin, Herceptin, Rituxan, Actemra, Xolair, and others. Revenue flows through specialty pharmacies, hospital sales, and direct patient distribution channels.
2. Co-commercialization Revenue: Venclexta (venetoclax) is jointly commercialized by AbbVie and Genentech in the U.S., representing a co-commercialization partnership revenue stream.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Genentech develops, manufactures, and commercializes a broad portfolio of biopharmaceutical medicines across oncology, immunology, neuroscience, ophthalmology, and metabolic diseases. Its products include monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, gene therapies, and small molecule drugs such as Tecentriq, Herceptin, Avastin, Ocrevus, Vabysmo, Hemlibra, Venclexta, Polivy, and Susvimo. The company distributes these medicines through specialty pharmacies, hospital channels, and direct patient assistance programs, while also operating a patient foundation providing free medicines to uninsured individuals.

Product overview

Genentech's product portfolio is a diverse platform of biotechnology medicines spanning multiple therapeutic areas including oncology (Avastin, Herceptin, Tecentriq, Venclexta, Polivy, Lunsumio, Columvi, Alecensa, Kadcyla, Perjeta, Phesgo, Rozlytrek, Itovebi), immunology (Rituxan, Gazyva, Ocrevus, Xolair, Actemra), ophthalmology (Lucentis, Vabysmo, Susvimo), rare blood disorders (Hemlibra, PiaSky), neuroscience (Ocrevus, Enspryng), and infectious disease (Xofluza, Tamiflu). The portfolio includes both intravenous and subcutaneous formulations, with several products having received new indications or regulatory approvals recently, including expanded uses for Tecentriq in muscle-invasive bladder cancer and colon cancer, and Venclexta for chronic lymphocytic leukemia. The company also offers gene therapy (Luxturna) and has an advancing obesity portfolio including enicepatide and petrelintide in Phase III development. Genentech provides these medicines through patient support services including the Genentech Patient Foundation for those without insurance coverage.

Differentiator

Problem solved

Functional benefit

Brands

• Genentech Patient Foundation: A patient assistance program providing free Genentech medicines to people who don't have insurance coverage or who have financial concerns.
• Genentech Access Solutions
• MEDICALLY

Products and services

• Actemra (tocilizumab)
• Alecensa (alectinib)
• Avastin (bevacizumab)
• Columvi (glofitamab-gxbm)
• Enspryng (satralizumab-mwge)
• Evrysdi (risdiplam)
• Gazyva (obinutuzumab)
• Hemlibra (emicizumab-kxwh)
• Herceptin (trastuzumab)
• Itovebi (inavolisib)
• Kadcyla (ado-trastuzumab emtansine)
• Lucentis (ranibizumab injection)
• Lunsumio (mosunetuzumab-axgb)
• Luxturna (voretigene neparvovec-rzyl)
• Ocrevus (ocrelizumab)
• Perjeta (pertuzumab)
• Phesgo
• PiaSky (crovalimab-akkz)
• Polivy (polatuzumab vedotin-piiq)
• Rituxan (rituximab)
• Rozlytrek (entrectinib)
• Susvimo
• Tecentriq (atezolizumab)
• Vabysmo (faricimab-svoa)
• Venclexta (venetoclax)
• Xofluza (baloxavir marboxil)
• Xolair (omalizumab)
• Zelboraf (vemurafenib)

Quantifiable outcome

• 59% reduction in risk of disease progression or death with Lunsumio VELO + Polivy combination vs comparator in relapsed/refractory large B-cell lymphoma (Phase III SUNMO study)
• +3 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature5 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• Prescient DesigncoreStrategic or Co-development Partner · 2 November 2021Genentech acquired Prescient Design to enhance antibody discovery capabilities through machine learning-based protein design. The acquisition was motivated by Prescient Design's unique platform and talented team, aiming to improve efficiency and effectiveness in identifying therapeutic antibodies.
• Sangamo TherapeuticscoreStrategic or Co-development PartnerSangamo's proprietary STAC-BBB capsid has been licensed to Genentech for up to $4.6 billion in potential milestones. The capsid enables brain-targeting gene therapies.
• NateracoreTechnology or IntegrationFDA approved Signatera CDx as companion diagnostic for Tecentriq in muscle-invasive bladder cancer. First blood-based MRD companion diagnostic approved, identifying patients who may benefit from Tecentriq after cystectomy.
• Lineage Cell TherapeuticscoreStrategic or Co-development PartnerWorldwide collaboration for OpRegen (RG6501) cell therapy for geographic atrophy secondary to age-related macular degeneration. Patients showed +9.0 ETDRS letters gain at 36 months with partial restoration of outer retinal structure.
• Recursion PharmaceuticalscoreStrategic or Co-development PartnerAI-powered drug development partnership advancing clinical candidates including REC-1245 and REC-4881. Genentech continues as partnered program collaborator following Recursion's partnership with Sanofi.
• Caris Life SciencesminorStrategic or Co-development PartnerDecember partnership with Genentech for molecular profiling services. Described as the largest pharma deal in Caris' history for precision oncology diagnostics.
• AbbViecoreStrategic or Co-development PartnerCo-commercialization of Venclexta (venetoclax) in the U.S. Venetoclax is co-developed by AbbVie and Roche/Genentech, with positive Phase III CLL14 trial data showing 6.4-year median PFS.
• Lupus Research AlliancecoreStrategic or Co-development PartnerCollaborative research program funding CAR-T cell therapy research for lupus. Inaugural recipients of Lupus Research Alliance-Genentech Award on Immune Resetting Therapies for Lupus each receive $150,000 per year for up to two years.
• National Multiple Sclerosis SocietycoreGTM or Marketing PartnerFunding MS Care Desert Initiative in South Carolina - Genentech's largest corporate sponsorship to date for the Society's healthcare access programs. Part of three-state pilot including Wisconsin and Mississippi.
• Precede BiosciencesminorStrategic or Co-development PartnerCollaboration at AACR 2026 for Precede Bio Insight liquid biopsy product enabling genome-wide inference of gene expression from 1mL plasma for predicting therapeutic response.
• BioNTechcoreStrategic or Co-development PartnerCo-development of personalized mRNA cancer vaccine (autogene cevumeran) for pancreatic cancer. 87.5% of patients with strong T cell responses remain alive 4-6 years post-surgery vs median survival of 3.4 years for non-responders.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Market position

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/genentech
• LinkedInlinkedin.com/company/genentech
• Xx.com/genentech
• Facebookfacebook.com/Genentech

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A6 records

Investments17 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genentech